Orchid Pharma Limited — Board Meeting, 14-08-2026: Outcome of Board Meeting

Orchid Pharma's board approved revised consolidated financial results for Q4 & FY26, reporting a Net Profit of ₹9.96 Cr. The results reflect the amalgamation with Dhanuka Labs and the acquisition of Allecra Therapeutics assets, securing 100% ownership of the antibiotic molecule Enmetazobactam. Auditors gave a modified opinion on consolidated financials due to unaudited subsidiary data.